EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Building the Bridge: How B2B Media Is Shaping the Future of Chemical Engineering
The shift is already well underway BB medias value used to be measured in reach how many engineers received your magazine how many clicks your digital...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
Forgotten Biology: The Missing Link Behind Trial Outcomes
Clinical trials are often described as the science of uncertainty and that uncertainty is expected It is how evidence is built However not all uncertainty is scientific In many cases it arises when the biological context of an intervention is not carried through into the study population
-
Techno Trends
FORE Biotherapeutics Receives FDA Breakthrough Therapy Designation for Plixorafenib in Brain Cancer
FORE Biotherapeutics has received Breakthrough Therapy Designation from the US Food and Drug Administration FDA for its investigational drug plixorafenib developed for the treatment of adult patients with BRAF VEmutated highgrade glioma a severe form of brain cancer
-
Projects
Cambrex Announces $150 Million Expansion across U.S. and European Facilities
Cambrex has revealed significant progress on its expansion initiatives across the United States and Europe These projects are designed to boost capacity for manufacturing complex drugs
-
Research Insights
Gene expression and metadata based identification of key genes for lung cancer, COPD, and IPF using machine learning and statistical models
Lung cancer LC is one of the most prevalent and deadly cancers globally presenting a major public health challenge Patients with chronic obstructive pulmonary disease COPD and idiopathic pulmonary fibrosis
-
White Papers
Accelerating In-Vitro Antibody Discovery with Artificial Intelligence
Antibodies have transformed modern medicine reshaping treatment paradigms across autoimmune disorders oncology and infectious diseases As one of the most versatile and successful therapeutic modalities
TOP ARTICLES
-
1
Boost Your Pharma Conference ROI: Proven Tactics to Increase Qualified Leads
Kate Williamson
Pharma conferences generate volume, but not always value. This article presents some viable measures to enhance the ROI of pharma conference through qualified lead generation process, targeted pre-eve...
-
2
Solutions from Technology to Innovation: Transforming Pharmaceutical Production in North America
Kate Williamson
The integration of technology is reshaping pharmaceutical production in North America, with automation, data analytics, 3D printing, regulatory compliance tools, blockchain, and remote monitoring play...
-
3
eCTD Compliance Guide: Best Practices for Pharmaceutical Regulatory Submissions
Kate Williamson
This guide examines the basics of eCTD compliance, with professional knowledge on the best practice of pharmaceutical regulatory submissions. It emphasizes global standards, lifecycle management, eCTD...
-
4
AI-Driven Trial Operations and Site Management: The AI-Powered Future of Clinical Research
Dr. Sandesh Nalawade
Clinical trial operations are undergoing a transformative shift driven by artificial intelligence (AI). AI technologies are revolutionising site selection, monitoring, and data management, enabling re...
-
5
Curcumin’s Role as an Anti-Neurofibrillary Agent Towards Alzheimer's Disease
Sabrina Ruoyao Chen Zhang
Ronny Priefer
Alzheimer’s disease is a progressive neurodegenerative disease that afflicts millions of people globally. Symptoms typically present as memory loss and cognitive decline. Existing hypthoses focu...
press releasesRead more...
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Inc Nasdaq IMNM a biotechnology company committed to developing firstinclass and bestinclass targeted cancer therapies today announced the submission of a New Drug Application NDA to the US Food and Drug Administration
Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
Insilico Medicine a clinicalstage generative AIdriven drug discovery company today announced that the inhalation solution of Rentosertib ISM the companys firstinclass drug candidate with AIidentified novel target
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
CRay Therapeutics Chengdu Co Ltd today announced that its Type II Drug Master File DMF for COPPER Cu CHLORIDE FOR RADIOLABELLING has been listed as active by the US Food and Drug Administration
Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
Xcovery Holdings Inc Xcovery an evidencebased innovationdriven pharmaceutical company today announced an agreement with EVERSANA a leading provider of commercialization services to the global life sciences
Events Read more...
05 - 06
May 2026GENAP Summit 2026
Vienna, Austria
06 - 07
May 20262nd Edition MaxPotent Pharma Summit 2026
Milan, Italy
06 - 07
May 202641th pharmacovigilance USA 2026
Boston, USA
07 - 08
May 202621st PPM for Pharma & Biotech
New Jersey, USA
10 - 14
May 2026Respiratory Drug Delivery 2026
The Westin Kierland Phoenix, Arizona, USA
20 - 21
May 2026Pharmacovigilance Europe 2026
London, UK
20 - 22
May 2026PHARMA EURASIA 2026
Pharma & Med Tech Park, Tashkent, Uzbekistan
20 - 21
May 2026Pharma Partnering EU Summit 2026
Basel Marriott Hotel, Switzerland
LATEST NEWSRead more...
Expression Therapeutics Secures FDA Fast Track and Rare Paediatric Disease Designations for Haemophilia A Therapy
Expression Therapeutics has received Fast Track and Rare Paediatric Disease designations from the US Food and Drug Administration for its investigational autologous stem cell therapy for haemophilia A
Formosa Pharmaceuticals and SERI Partner to Advance Ophthalmic Treatments for Corneal Diseases
Formosa Pharmaceuticals has entered into a strategic research partnership with the Singapore Eye Research Institute SERI to develop nextgeneration ophthalmic formulations for corneal and ocular surface diseases
Chiesi Acquires KalVista for $1.9B in Rare Disease Strategy
Chiesi Farmaceutici is acquiring KalVista Pharmaceuticals for billion to bolster its rare disease offerings with the approved HAE therapy Ekterly
Gilead Sciences completes acquisition of Arcellx ahead of potential anito-cel launch
Gilead Sciences has completed its acquisition of Arcellx strengthening its position ahead of a possible commercial launch of anitocabtagene autoleucel anitocel
Pfizer Extends Patent for Rare Disease Blockbuster
Pfizer announces key licensing deals to prolong patent exclusivity on its leading rare disease therapy bolstering longterm revenue projections amid competitive biopharma landscape
FDA approves CAPLYTA® (lumateperone) sNDA with new data showing reduced relapse risk in schizophrenia
Johnson Johnson has received approval from the US Food and Drug Administration FDA for a supplemental New Drug Application sNDA for CAPLYTA lumateperone The approval is based on longterm data assessing its safety and effectiveness in preventing relapse in adults with schizophrenia
